Improvement of the pharmacokinetics and in Vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4816-4824

  Shapiro, Adam B ^a   Newman, Joseph ^a   Goteti, Kosalaram ^a,b   Beaudoin, Marie Eve ^a   Harrison, Rane ^a   Hopkins, Sussie ^a   Agrawal, Nikunj ^a   Rivin, Olga ^a  

^a ASTRAZENECA   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [2 [4 ([(2,3 DIHYDRO 1,4 DIOXINO(2,3 C) PYRIDIN 7 YL) METHYL]AMINO] 1 PIPERIDINYL]ETHYL] 1,2 DIHYDRO 2 OXO 7 QUINOLINECARBONITRILE]; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE INHIBITOR; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; FEMALE; LIPOSOMES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TOPOISOMERASE II INHIBITORS;

EID: 84884276513     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00163-13     Document Type: Article

References (29)

1. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Koretke Brown K, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940.
2. Black M, Stachyra T, Platel D, Girard A-M, Claudon M, Bruneau J-M, Miossec C. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother. 52:3339-3349.
3. Geng B, Comita-Prevoir J, Eyermann CJ, Reck F, Fisher S. 2011. Exploring left-hand-side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors. Bioorg. Med. Chem. Lett. 21:5432-5435.
4. Shapiro AB, Andrews B. 2012. Allosteric inhibition of the DNAdependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors. Biochem. Pharmacol. 84:900-904.
5. Fenske DB, Cullis PR. 2005. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 391:7-40.
6. Samad A, Sultana Y, Aqil M. 2007. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 4:297-305.
7. Drulis-Kawa Z, Dorotkiewicz-Jach A. 2010. Liposomes as delivery systems for antibiotics. Int. J. Pharm. 387:187-198.
8. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51:691-743.
9. Juliano RL. 1988. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. Rev. 2:31-54.
10. Bakker-Woudenberg IAJM, Schiffelers RM, Becker MJ, Guo L. 2005. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol. 391:228-260.
11. Schiffelers R, Storm G, Bakker-Woudenberg I. 2001. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48:333-344.
12. Schiffelers RM, Storm G, Bakker-Woudenberg IAJM. 2001. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm. Res. 18:780-787.
13. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387- 6392.
14. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske D. 1997. Influence of pH gradients on the transbilayer transport of drug, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta 1331:187-211.
15. Bakker-Woudenberg IAJM, Ten Kate MT, Guo L, Working P, Mouton JW. 2001. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae in rats. Antimicrob. Agents Chemother. 45:1487-1492.
16. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, Doroszkiewicz W, Kozubek A. 2006. A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin. Cell. Mol. Biol. Lett. 11:360-375.
17. Maurer N, Wong KF, Hope MJ, Cullis PR. 1998. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1HNMR study. Biochim. Biophys. Acta 1374:9-20.
18. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. 1999. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim. Biophys. Acta 1416:1-10.
19. Sachetelli S, Khalil H, Chen T, Beaulac C, Sénéchal S, Lagacé J. 2000. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta 1463:254- 266.
20. Schiffelers RM, Storm G, Ten Kate MT, Bakker-Woudenberg IAJM. 2001. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin. Antimicrob. Agents Chemother. 45:464-470.
21. Nayar R, Hope MJ, Cullis PR. 1989. Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique. Biochim. Biophys. Acta 986:200-206.
22. Tam VH, Chang K, Yang JV, Newman JV, Hu M. 2013. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob. Agents Chemother. 57:1062-1064.
23. Allen TM, Everest JM. 1983. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther. 226:539-544.
24. Kirby C, Clarke J, Gregoriadis G. 1980. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186:591-598.
25. Bakker-Woudenberg IAJM, Ten Kate MT, Stearne-Cullen LET, Woodle MC. 1995. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis. 171:938-947.
26. Schiffelers RM, Bakker-Woudenberg IAJM, Storm G. 2000. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene) glycol coating. Biochim. Biophys. Acta 1468:253-261.
27. Schiffelers RM, Bakker-Woudenberg IAJM, Snijders SV, Storm G. 1999. Localization of sterically stabilized liposomes in Klebsiella pneumoniaeinfected rat lung tissue: influence of liposome characteristics. Biochim. Biophys. Acta 1421:329-339.
28. Morotti M, Menada MV, Venturini PL, Ferrero S. 2011. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. Expert Opin. Drug Metab. 7:707-720.
29. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. 2008. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97:2405- 2425.